Gene Therapy Clinical Trials
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Stanford is currently not accepting patients for this trial.
Eligibility
Inclusion Criteria
Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms
(MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:
- Present for an AML-like treatment that could plausibly produce a complete remission
(CR); for example intensive induction chemotherapy, low dose single agent
chemotherapy, hypomethylation agent, or a similar therapy
- Possibility to retrieve follow-up records from the collaborating institution or
treating primary care physician
- Patients with primary refractory or first relapse presenting for salvage chemotherapy
will be allowed
- Patients of 18 years of age or older, and are being treated by the adult AML service.
- Able to speak and read English.
- Willing and able to provide informed consent.
Exclusion Criteria
- Patients of ≤17 years of age or who are 18 or older and receive treatment under the
pediatric AML service.
- Patients older than 80 years
- Patients with <6 months projected survival due to active second malignancy or other
medical problem.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting